IBIO INC
IBIONASDAQTrading Snapshot
- Day Range
- $1.45 – $1.50
- 52-Week Range
- $0.56 – $3.82
- Volume
- $2.84B
- Avg Volume
- $3.40B
- Shares Outstanding
- 49.7M
- Next Earnings
- Sep 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $400,000
- Last Q Revenue
- $109,766
- P/E Ratio
- —
- P/S Ratio
- 140.1x
- EPS (TTM)
- $-0.83
- Dividend Yield
- —
Why Investors Own IBIO
- ✓High-growth profile — revenue up +48.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 69% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About IBIO INC
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
